CD274 and hepatocellular carcinoma: This observation provides a partial rationale for the superior efficacy of anti-PD-1 and anti-PD-L1 immunotherapy among high ERGs group patients with HCC, emphasizing the important value of the ERGs model in immunotherapy strategies (Figure 6).